Masato Terashima

Osaka, 5898511, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

Journal: International journal of oncology
Published: December 06, 2016

MEK inhibitors against MET-amplified non-small cell lung cancer.

MEK inhibitors against MET-amplified non-small cell lung cancer.

Journal: International journal of oncology
Published: August 04, 2016

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).

Journal: BMC cancer
Published: June 17, 2016

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.

Journal: Cancer science
Published: April 14, 2016

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

Journal: BMC cancer
Published: April 14, 2016

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Journal: Cancer science
Published: March 24, 2016

Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.

Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.

Journal: Molecular carcinogenesis
Published: November 26, 2015

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.

Journal: Molecular cancer therapeutics
Published: October 14, 2015

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.

Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 26, 2015

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.

MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 26, 2015

Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.

Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.

Journal: Cancer
Published: May 27, 2015

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.

EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition.

Journal: International journal of oncology
Published: April 15, 2015
Showing 1-12 of 25

Last Updated: 09/26/2026